about
Human cytochrome P450 oxidoreductase deficiency caused by the Y181D mutation: molecular consequences and rescue of defect.DNA polymorphisms as modulators of genotoxicity and cancer.Altered human CYP3A4 activity caused by Antley-Bixler syndrome-related variants of NADPH-cytochrome P450 oxidoreductase measured in a robust in vitro systemInstability of the Human Cytochrome P450 Reductase A287P Variant Is the Major Contributor to Its Antley-Bixler Syndrome-like Phenotype.Prototype Systems Containing Human Cytochrome P450 for High-Throughput Real-Time Detection of DNA Damage by Compounds That Form DNA-Reactive Metabolites.Cytochrome P450 expression system for high-throughput real-time detection of genotoxicity: Application to the study of human CYP1A2 variants.Alkylating potential of oxetanes.Impairment of human CYP1A2-mediated xenobiotic metabolism by Antley-Bixler syndrome variants of cytochrome P450 oxidoreductase.Functional characterization of eight human cytochrome P450 1A2 gene variants by recombinant protein expression.The stimulatory role of human cytochrome b5 in the bioactivation activities of human CYP1A2, 2A6 and 2E1: a new cell expression system to study cytochrome P450 mediated biotransformation.Escherichia coli BTC, a human cytochrome P450 competent tester strain with a high sensitivity towards alkylating agents: involvement of alkyltransferases in the repair of DNA damage induced by aromatic amines.Editorial: Role of Protein-Protein Interactions in Metabolism: Genetics, Structure, Function.The Hinge Segment of Human NADPH-Cytochrome P450 Reductase in Conformational Switching: The Critical Role of Ionic Strength.Simple and sensitive antimalarial drug screening in vitro and in vivo using transgenic luciferase expressing Plasmodium berghei parasites.Expression of human cytochrome P450 1A2 in Escherichia coli: a system for biotransformation and genotoxicity studies of chemical carcinogens.Genotoxicity and endoreduplication inducing activity of the food flavouring eugenol.MX100, a new Escherichia coli tester strain for use in genotoxicity studies.Correction: The Hinge Segment of Human NADPH-Cytochrome P450 Reductase in Conformational Switching: The Critical Role of Ionic Strength.Probing the Role of the Hinge Segment of Cytochrome P450 Oxidoreductase in the Interaction with Cytochrome P450Human cytochrome P450 expression in bacteria: Whole-cell high-throughput activity assay for CYP1A2, 2A6 and 3A4Non-specific binding of the fluorescent beta-adrenergic receptor probe alprenolol-NBDEscherichia coli MTC, a NADPH cytochrome P450 reductase competent mutagenicity tester strain for the expression of human cytochrome P450: comparison of three types of expression systemsEscherichia coli MTC, a human NADPH P450 reductase competent mutagenicity tester strain for the expression of human cytochrome P450 isoforms 1A1, 1A2, 2A6, 3A4, or 3A5: catalytic activities and mutagenicity studiesThe stimulatory role of human cytochrome b5 in the bioactivation activities of human CYP1A2, 2A6 and 2E1: a new cell expression system to study cytochrome P450-mediated biotransformation (a corrigendum report on Duarte et al. (2005) Mutagenesis 20,Human sulfotransferase 1A1-dependent mutagenicity of 12-hydroxy-nevirapine: the missing link?
P50
Q33613333-3C5EBBAF-B432-4F78-994F-9251F317A494Q34835526-B6035C64-0BB7-487B-BF56-E880D0C6EF43Q35846903-894CBCC3-8555-4DC3-996D-730C63BAED2CQ38753508-017D395A-6B21-48F5-8AAD-173D2431606DQ38887785-85262478-101E-4156-8B62-DD7A608C84FAQ40394201-1511BE16-3828-4DA3-9A6C-D2E2D1D1EEB0Q43021921-1B07738E-1957-4086-988E-57F06D84E4F2Q43069462-3C9312A0-03B8-4A04-81DF-306B89CCE42FQ43177116-21A7365D-5167-4782-90B2-A54D023FC74FQ45280608-702A49E7-58D9-4C4A-82BE-1C92B06E72FDQ46447960-3DE635F1-5C69-4EF4-BB5D-8A9BEA4FFA68Q47096419-A8F336ED-5C11-4151-ACC7-60ABBD776C40Q47104690-806220BD-0055-49EA-8EF3-FB05F2A2C862Q47871519-E572714B-2002-4885-8005-F3E1EFBFB98EQ47918980-B03D6A9E-1B85-4B7C-8FF3-1F57887A743CQ51808791-492A8E82-8324-4D83-82E8-CB9A0FD855CFQ54586594-FFAA7F7F-258A-41EB-A61C-653E29A3FBB0Q55072871-EE1B32F3-44AD-41A8-82C8-7714CC735FF0Q60912674-663A9D05-686D-448A-8F65-4DCD5CC85995Q61659608-5B5A7B0E-5622-41FD-AC93-1B58BF6FCD94Q70097688-DE33B8D6-E8AB-48D6-8973-7A8E1AE76DAAQ74450526-D3037E95-E2CA-43CE-AD3E-CACF3D85BD57Q77388769-D505B72D-E2B7-4BA6-A8D3-B95A1E6E61B6Q79422150-F4700EA8-A918-430F-8877-11F27B870876Q85665945-FD0E6DE8-DDD0-442B-92D7-E42F335C3A3A
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Michel Kranendonk
@ast
Michel Kranendonk
@en
Michel Kranendonk
@es
Michel Kranendonk
@nl
Michel Kranendonk
@sl
type
label
Michel Kranendonk
@ast
Michel Kranendonk
@en
Michel Kranendonk
@es
Michel Kranendonk
@nl
Michel Kranendonk
@sl
prefLabel
Michel Kranendonk
@ast
Michel Kranendonk
@en
Michel Kranendonk
@es
Michel Kranendonk
@nl
Michel Kranendonk
@sl
P106
P1153
6603648823
P31
P496
0000-0003-1362-0076